* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Bacteriophage-mediated nucleic acid immunisation
Genealogical DNA test wikipedia , lookup
Gene therapy wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
United Kingdom National DNA Database wikipedia , lookup
Gel electrophoresis of nucleic acids wikipedia , lookup
Primary transcript wikipedia , lookup
Genetic engineering wikipedia , lookup
Non-coding DNA wikipedia , lookup
Cell-free fetal DNA wikipedia , lookup
Nucleic acid double helix wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Epigenetics in learning and memory wikipedia , lookup
DNA damage theory of aging wikipedia , lookup
DNA supercoil wikipedia , lookup
Epigenomics wikipedia , lookup
Point mutation wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Extrachromosomal DNA wikipedia , lookup
Molecular cloning wikipedia , lookup
Microevolution wikipedia , lookup
Genomic library wikipedia , lookup
Nucleic acid analogue wikipedia , lookup
Designer baby wikipedia , lookup
No-SCAR (Scarless Cas9 Assisted Recombineering) Genome Editing wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Helitron (biology) wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Cre-Lox recombination wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
History of genetic engineering wikipedia , lookup
FEMS Immunology and Medical Microbiology 40 (2004) 21^26 www.fems-microbiology.org Bacteriophage-mediated nucleic acid immunisation Jason R. Clark, John B. March Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, UK Received 28 August 2003 ; received in revised form 9 September 2003; accepted 10 September 2003 First published online 27 November 2003 Abstract Whole bacteriophage V particles, containing reporter genes under the control of the cytomegalovirus promoter (PCMV ), have been used as delivery vehicles for nucleic acid immunisation. Following intramuscular injection of mice with V-gt11 containing the gene for hepatitis B surface antigen (HBsAg), anti-HBsAg responses in excess of 150 mIU ml31 were detected. When isolated peritoneal macrophages were incubated with whole V particles containing the gene for green fluorescent protein (GFP) under the control of PCMV , GFP antigen was detected on the macrophage surface 8 h later. Results suggested that direct targeting of antigen-presenting cells by bacteriophage ‘vaccines’ may occur, leading to enhanced immune responses compared to naked DNA delivery. Bacteriophage DNA vaccines offer several advantages: they do not contain antibiotic resistance genes, they offer a large cloning capacity (V15 kb), the DNA is protected from environmental degradation, they offer the potential for oral delivery, and large-scale production is cheap, easy and extremely rapid. ; 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. Keywords : DNA vaccination ; Bacteriophage; Hepatitis B; Vaccine delivery 1. Introduction Nucleic acid immunisation consists of inoculating a target animal with puri¢ed DNA or RNA containing a gene(s) under the control of an exogenous eukaryotic promoter, so that protective antigens are expressed within the host [1,2]. Nucleic acid vaccines potentially have a number of advantages over traditional attenuated, killed or subunit vaccines. They are cheaper and easier to produce than recombinant protein vaccines, have fewer adverse side effects and induce both cellular (Th1) and humoral (Th2) arms of the immune system. Studies in mice have demonstrated good antibody [2] and cellular [3] responses with nucleic acid vaccines, and in some examples protection against disease [4,5], but trials in larger animals, humans and non-human primates have been plagued by a lack of * Corresponding author. Tel. : +44 (131) 445 5111 ; Fax : +44 (131) 445 6235. E-mail address : [email protected] (J.B. March). e⁄cacy when using naked DNA [6]. A number of methods have been tested to improve responses against DNA vaccines and have been reviewed [7]. These include gene gun delivery [5], association with liposomes [8] or other microparticles [9], or the inclusion of cytokines [10], chemokines [11], or immunostimulatory CpG motifs [12] in the vaccine vector or in co-injected nucleic acid. However, many of these methods signi¢cantly increase the cost or ease of production of DNA vaccines, while others can present regulatory hurdles and alternative ways to improve responses are still being sought. We have cloned a number of DNA vaccination cassettes into standard bacteriophage V vectors and used these whole phage particles, rather than puri¢ed DNA, as a delivery vehicle for DNA vaccination. We have tested antibody responses and/or antigen expression using ¢ve di¡erent phage vaccines : single gene reporter constructs containing the gene for green £uorescent protein (VGFP) or hepatitis B surface antigen (V-HBsAg), a whole genome library of the bovine pathogen Mycoplasma mycoides subspecies mycoides small colony type (V-MmmSC), a single immunodominant lipoprotein clone picked from this library (V-B1) and a whole genomic library of the caprine pathogen Mycoplasma capricolum subspecies capripneumoniae (V-Mccp). Typical results are presented here, with more detailed information being available [13]. 0928-8244 / 03 / $22.00 ; 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. doi:10.1016/S0928-8244(03)00344-4 FEMSIM 1652 15-12-03 Cyaan Magenta Geel Zwart 22 J.R. Clark, J.B. March / FEMS Immunology and Medical Microbiology 40 (2004) 21^26 2. Materials and methods 2.3. Immunisation of mice 2.1. Construction of V vaccines Mice were vaccinated twice at weeks 0 and 3 with either HBsAg phage vaccine constructs, control phage, or HBsAg protein. The eight groups used were as follows : (a) 5U1011 plaque-forming units (pfu) negative control V-gt11 given i.m. in 50 Wl saline bu¡er ; (b) 25 Wg control pCMV-HBs plasmid DNA (5U1012 copies) given i.m. in 50 Wl saline; (c) 1011 freeze-dried phage particles delivered subcutaneously by Helios gene gun (Bio-Rad); (d) 5U1011 pfu V-HBsAg complexed with liposomes (Transfectam, Promega, cat. no. E1232), given i.m. in 50 Wl saline bu¡er; (e) 5U1011 V-HBsAg in saline/Montanide ISA 206 oil adjuvant given i.m. in a total volume of 50 Wl; (f) 5U1011 pfu V-HBsAg given i.m. in 50 Wl saline bu¡er ; (g) 5U1011 V-HBsAg complexed with chitosan (Fluka) in saline bu¡er, administered in 5 Wl per nostril; (h) 1 Wg of recombinant HBsAg (Aldeveron) delivered i.m. in 50 Wl endotoxin-free saline. Ten mice were used per group. Whole genome libraries of Mccp and MmmSC were made by cloning Tsp509I partial digests into the EcoRI site of the VZAP express vector (Stratagene). The V-B1 clone was selected from the MmmSC library by performing plaque lifts and Western blotting with bovine convalescent and rabbit hyperimmune serum raised against MmmSC. Plaques which showed good responses against both sera were picked, ampli¢ed and stored. This selection was possible since insert genes cloned into the VZAP Express vector are under the control of both a prokaryotic (lacZ) and a eukaryotic (cytomegalovirus, CMV) promoter. V-EGFP was prepared by linearising plasmid pEGFPC1 (Clontech) with EcoRI, and cloning the whole plasmid into EcoRI-digested V-gt11 DNA. V-HBsAg was prepared by linearising plasmid prcCMV-HBs(S) (Aldeveron) with MfeI (which gives EcoRI-compatible ends) and cloning the whole plasmid into the EcoRI site of V-gt11. 2.2. In vitro uptake of bacteriophage by macrophage Prior to the experiment, two mice were inoculated in the peritoneal cavity with 1.5 ml 3% thioglycollate broth. After 3^4 days the mice were killed and the peritoneal cavities washed with 6 ml phosphate-bu¡ered saline (PBS). The peritoneal exudate (containing macrophages) was spun at 250Ug and 4‡C and the pellet re-suspended in 0.3% saline to lyse red blood cells. The macrophage suspension was again spun and the pellet re-suspended in 1 ml of serum-free RPMI 1640, counted and added to 24-well tissue culture plates at a concentration of 5U106 cells per well in a volume of 1 ml. Macrophages were incubated at 37‡C for 30 min, before the supernatant was removed and wells washed once with serum-free RPMI to remove nonadherent cells. 1 ml RPMI+10% foetal bovine serum was added to each well along with bacteriophage (1011 per well) or naked DNA (25 Wg per well). Plates were incubated overnight at 37‡C. After incubation, macrophages were detached by placing plates at 4‡C for 1 h and the cells re-suspended with a wide-bore pipette. 10 ml PBS was added to the cells which were centrifuged at 250Ug and 4‡C for 10 min, before washing twice. Cells were then spun onto charged microscope slides at a concentration of 5U105 cells per slide. Macrophages were stained immunohistochemically using a Vectastain Elite Universal ABC kit (PK-6200) as per the manufacturer’s instructions, with speci¢c anti-GFP rabbit polyclonal primary antiserum (Invitrogen, cat. no. R970-01). After immunostaining, cells were visualised by counter-staining with haematoxylin, before dehydration and mounting. FEMSIM 1652 15-12-03 2.4. Measurement of antibody responses Antibody responses against recombinant HBsAg or bacteriophage V coat proteins were measured by indirect enzyme-linked immunosorbent assay (ELISA). Serum samples were taken every 2 weeks from week 0 onwards. Mice were killed and bled out at di¡erent stages throughout the experiment: for mice numbers 1^2 in each group, four bleeds were tested (weeks 0^6), for mice 3^6, ¢ve bleeds were tested (weeks 0^8), and for mice 7^10, six bleeds were tested (weeks 0^10). ELISA plates were coated overnight in 0.05 M sodium carbonate bu¡er at pH 9.2 with either 100 ng of puri¢ed HBsAg (Aldeveron) or 109 bacteriophage per well. Coating bu¡er was then removed and 200 Wl per well blocking bu¡er (5% Marvel dry skimmed milk in PBS-Tween) was added for 30 min at 37‡C. Blocking bu¡er was then removed and primary antibody was added at a dilution of 1:100 in blocking bu¡er at 100 Wl per well and plates were incubated for 3 h at 37‡C. Plates were then washed ¢ve times in PBS-Tween and horseradish peroxidase secondary antibody (Dako) added for 1 h at 37‡C at the manufacturer’s recommended dilution. Plates were then washed ¢ve times in PBS-Tween and 200 ml per well substrate (Sigma Fast-OPD tablets) added and the plates developed for 10 min in the dark. The reaction was stopped by the addition of 50 ml per well of 3 M H2 SO4 and the optical density read at 492 nm. Selected serum samples had the anti-HBsAg response quanti¢ed by comparison to international standards (Bio-Rad Monolisa Standards, cat. no. 72399). 2.5. Statistical analysis A one-way analysis of variance using Tukey’s multiple comparison test was used. Cyaan Magenta Geel Zwart J.R. Clark, J.B. March / FEMS Immunology and Medical Microbiology 40 (2004) 21^26 Fig. 1. Expression of cloned inserts in APCs. Mouse peritoneal macrophage were cultured overnight in the presence of (a) V-GFP or (b) unmodi¢ed control V-gt11 and immunohistochemically stained for the presence of expressed protein. The large panel shows macrophage counterstained with haematoxylin at U40 magni¢cation. The smaller circled panel shows uncounterstained macrophage at U1 magni¢cation. Macrophage cultured with V-GFP showed signi¢cantly more staining than those cultured with control phage. 3. Results and discussion Being a particulate antigen, bacteriophage are rapidly taken up by antigen-presenting cells (APCs) [14], and following injection they are targeted to the spleen and liver Kup¡er cells (where they persist for several days) [15]. To demonstrate the uptake of phage particles and expression of cloned inserts by APCs in vitro, reporter phage (V-GFP) were added to activated mouse peritoneal macrophages, and GFP expression on the cell surface was demonstrated by immunohistological staining (Fig. 1). Similar results were seen with macrophage cultured with V-B1 (data not shown), suggesting that direct immune priming by professional APCs should occur in mice following injection with phage ‘DNA’ vaccines. This is in agreement with earlier research where whole adenovirus particles containing a L-galactosidase reporter gene under the control of a eukaryotic promoter were used to transduce macrophages. Subsequent staining of transduced macrophages with X-gal showed expression of the reporter protein [16]. However, since V phage (containing inserts under the control of a eukaryotic promoter) have also been shown to be capable of directly transducing mammalian cells in culture [17], it is possible that indirect priming via non-speci¢c cellular uptake of the phage may also be occurring. To study antibody responses following ‘phage vaccination’ in vivo, BALB/c mice were administered 1011 pfu FEMSIM 1652 15-12-03 23 V-HBsAg phage i.m. in either saline bu¡er, oil adjuvant or in association with liposomes. Recombinant phage were also administered nasally after association with the mucosal adjuvant chitosan [18] and by gene gun after freeze drying. Control mice were immunised with unmodi¢ed V-gt11 phage (i.m. in bu¡er), HBsAg protein (1 Wg i.m. in bu¡er) and naked DNA (plasmid prcCMV-HBs(S), i.m. in bu¡er). Ten mice were used per group and antibody responses were measured against bacteriophage coat proteins and against recombinant HBsAg (with a control monoclonal antibody used to allow comparison between plates) by ELISA. Summarised results are shown in Fig. 2. All three mouse groups vaccinated i.m. with V-HBsAg showed signi¢cantly higher HBsAg antibody responses than groups vaccinated with plasmid prcCMV-HBs(S) or unmodi¢ed V-gt11 (P 6 0.01, comparison of ¢nal bleeds). Anti-HBsAg responses in excess of 150 mIU ml31 were observed in mice injected i.m. with V-HBsAg (Fig. 2d, animal 4, ¢nal bleed), whereas the internationally recognised level for protection is 10 mIU ml31 [19]. All 30 mice vaccinated i.m. with V-HBsAg showed signi¢cant (P 6 0.01) anti-HBsAg responses compared to the pre-immunisation signal (Fig. 2d^f). There was no signi¢cant di¡erence in the anti-HBsAg responses between these three groups, indicating that phage-mediated DNA vaccination is as e¡ective when delivered in bu¡er as in adjuvant or liposomes. In contrast, plasmid-based DNA vaccination is reported to be signi¢cantly more e¡ective when administered with liposomes [20]. In certain animals in which phage were co-administered with adjuvant, some transient trauma was seen at the site of injection, however, no adverse reactions were noted in the other groups. Gene gun immunisation gave poor responses against both HBsAg (Fig. 2c) and phage coat proteins (Fig. 3b), suggesting ine⁄cient delivery of phage particles by this route. In our test, freeze-dried phage particles were applied directly without prior attachment to gold beads. This could explain the variable responses to both HBsAg and phage coat proteins seen with this group (i.e. poor epithelial penetration) and suggests that with modi¢cation, gene gun delivery of phage DNA vaccines could be a viable proposition. With standard gene gun immunisation, DNA is bound to gold particles before in vivo delivery using high pressure helium. In addition, subsequent research in our laboratory (unpublished results) has shown that bacteriophage V displays a 1^2 log10 drop in titre when freezedried in the absence of any stabilisers, which may also have contributed to the lower anti-HBsAg response following vaccination by this route. Mice vaccinated nasally with V-HBsAg in combination with chitosan showed no response against HBsAg (Figs. 2g and 3a for group average responses) but did show a response against the phage coat proteins (Fig. 3b). This indicated that phage antigens were successfully delivered, but that the insert was not being expressed, either because the mechanism of phage uptake was di¡erent following mucosal immunisation, or Cyaan Magenta Geel Zwart 24 J.R. Clark, J.B. March / FEMS Immunology and Medical Microbiology 40 (2004) 21^26 Fig. 2. HBsAg antibody responses in mice inoculated with phage vaccines measured by ELISA. a: 5U1011 pfu negative control V-gt11 given i.m. in 50 Wl saline bu¡er. b: 25 Wg control pCMV-HBs plasmid DNA (5U1012 copies) given i.m. in 50 Wl saline. c : 1011 freeze-dried phage particles delivered subcutaneously by Helios gene gun (Bio-Rad). d: 5U1011 pfu V-HBsAg complexed with liposomes (Transfectam, Promega, cat. no. E1232), given i.m. in 50 Wl saline bu¡er. Arrow indicates response of 150 mIU when response was compared to international standards (Bio-Rad Monolisa standards, cat. no. 72399). e: 5U1011 V-HBsAg in saline/Montanide ISA 206 oil adjuvant given i.m. in a total volume of 50 Wl. f: 5U1011 pfu V-HBsAg given i.m. in 50 Wl saline bu¡er. g: 5U1011 V-HBsAg complexed with chitosan in saline bu¡er, administered in 5 Wl per nostril. h: 1 Wg of recombinant HBsAg delivered i.m. in 50 Wl endotoxin-free saline. Ten mice were used per group. Black bars are control (pre-vaccination) bleeds and each grey bar represents one bleed per mouse. Mice were killed at di¡erent stages throughout the experiment, so not all animals were bled at every time point. Final bleeds occurred 6^10 weeks after vaccination and identically numbered mice are always comparable between groups. because the phage particles had been compromised during complexing with chitosan. In general, DNA vaccines do not raise high antibody responses but prime the immune system, protecting against subsequent infection. In a mouse experiment where vaccination with V-Mccp was followed by inoculation with whole M. capricolum subsp. capripneumoniae, the ratio of IgG1 to IgM was s 5:1 in serum extracted after challenge, indicative of a secondary immune response and successful priming by the phage vaccine, whereas serum from a mouse which had been vaccinated with a control phage only gave a ratio of 1.35:1, indicating a primary response [13]. Our study has shown that bacteriophage-mediated DNA vaccination consistently gave better antibody responses when compared to naked DNA, although plasmid copy numbers were 50^200 times higher than phage copy numbers. Although a strong antibody response was also seen against the carrier phage V coat proteins, this may actually enhance the e⁄ciency of the delivery system, since the formation of immune complexes should more e¡ectively target APCs following boosting. In all experiments to date we have observed greatly increased ‘vaccine’ anti- FEMSIM 1652 15-12-03 body titres following a second injection (sometimes up to 8 weeks after the primary immunisation; data not shown). This would suggest that an initial priming of the immune system against the phage carrier may be important, and speci¢c experiments to investigate the in£uence of the antiphage response on the e⁄ciency of the system are under way. Further work is also under way on the characterisation of cellular immune responses and in more detailed challenge studies. Compared to standard naked DNA technology, the system o¡ers several advantages: vaccine nucleic acid is contained within a stable matrix which appears to both target APCs and protect it from nuclease degradation. Expression constructs of up to 15^20 kb in size can be used in a standard bacteriophage V vector, raising the possibility that multiple vaccines can be delivered within a single phage (including cytokine ‘adjuvants’), or that large eukaryotic intron-containing genes can be used directly as nucleic acid vaccines. Multiple gene constructs should be particularly useful against diseases such as malaria or trypanosomiasis, in which parasites with complex life cycles or antigen switching are involved. In addition, simultaneous vaccination against several disease serotypes using Cyaan Magenta Geel Zwart J.R. Clark, J.B. March / FEMS Immunology and Medical Microbiology 40 (2004) 21^26 25 Acknowledgements We thank Catherine Jepson, Ray McInnes and Louise Gibbard for technical support and expertise and Jill Sales of BIOSS for statistical analysis. This work was funded by the Scottish Enterprise Proof of Concept fund and the Edinburgh Technology Fund. References Fig. 3. Comparison of 10 averaged ¢nal bleeds from each group against (a) HBsAg protein and (b) unmodi¢ed V-gt11 bacteriophage by ELISA. Results are normalised against a standard positive control on each ELISA plate to allow an accurate comparison between groups. For HBsAg plates a monoclonal antibody (clone NF5, Aldeveron) was used at a dilution of 1:50 000, while a mouse polyclonal antiserum (1:500) was used for the phage-coated plates. The signal from each test sample was normalised to the signal from this standard to allow the relative signal to be compared between di¡erent plates. Mice vaccinated with V-HBsAg showed signi¢cantly higher responses against HBsAg compared to V-gt11 alone, when phage are given in liposomes, Montanide and saline. *P = 0.01, **P = 0.001. a single construct should be possible. Nucleic acid vaccines prepared using this technology can be easily and inexpensively prepared to a high yield (su⁄cient phage to deliver millions of doses could be grown up in a few days, an important consideration bearing in mind the current threat of bio-terrorism). Compared to viruses of eukaryotic organisms, there should be no possibility of vaccine replication in host tissue, and phage do not carry antibiotic resistance genes, thus removing signi¢cant potential barriers to regulatory approval. Bacteriophages have been used in eastern Europe since the 1930s as systemic bactericidal agents [21], and thus there is a long history regarding large-scale manufacturing and their use in human healthcare to draw upon. Finally, studies in animals [22] and man [23] have shown that signi¢cant titres (103 ^106 per g tissue) of bacteriophage are found in tissues such as the spleen and liver following oral administration, suggesting that parenteral delivery may not be necessary for the effective use of phage vaccines. A simple vaccination strategy involving oral delivery of phage tablets or liquid suspensions may be all that is required. FEMSIM 1652 15-12-03 [1] Wol¡, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A. and Felgner, P.L. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465^1468. [2] Tang, D.C., De Vit, M. and Johnston, S.A. (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152^154. [3] Dietrich, G., Gentschev, I., Hess, J., Ulmer, J.B., Kaufmann, S.H. and Goebel, W. (1999) Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today 20, 251^253. [4] Nossal, G.J. and Lambert, P.H. (1997) The Jennerian heritage : new generation vaccines for all the world’s children and adults. Biologicals 25, 131^135. [5] Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C. and Robinson, H.L. (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90, 11478^11482. [6] Manickan, E., Karem, K.L. and Rouse, B.T. (1997) DNA vaccines ^ a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17, 139^154. [7] Leitner, W.W., Ying, H. and Restifo, N.P. (1999) DNA and RNAbased vaccines : principles, progress and prospects. Vaccine 18, 765^ 777. [8] Gregoriadis, G. (1999) DNA vaccines : a role for liposomes. Curr. Opin. Mol. Ther. 1, 39^42. [9] Singh, M., Briones, M., Ott, G. and O’Hagan, D. (2000) Cationic microparticles : A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 97, 811^816. [10] Conry, R.M., Widera, G., LoBuglio, A.F., Fuller, J.T., Moore, S.E., Barlow, D.L., Turner, J., Yang, N.S. and Curiel, D.T. (1996) Selected strategies to augment polynucleotide immunization. Gene Ther. 3, 67^74. [11] Scheerlinck, J.Y. (2001) Genetic adjuvants for DNA vaccines. Vaccine 19, 2647^2656. [12] Tighe, H., Corr, M., Roman, M. and Raz, E. (1998) Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19, 89^97. [13] March, J.B. (2002) Bacteriophage-mediated immunisation. World Patent WO 02/076498. [14] Aronow, R., Danon, D., Shahar, M.D. and Aronson, M. (1964) Electron microscopy of in vitro endocytosis of T2 phage by cells from rabbit peritoneal exudate. J. Exp. Med. 120, 943^954. [15] Keller, R. and Engley, F.B. (1958) Fate of bacteriophage particles induced into mice by various routes. Proc. Soc. Exp. Biol. Med. 98, 577. [16] Gri⁄ths, L., Binley, K., Iqball, S., Kan, O., Maxwell, P., Ratcli¡e, P., Lewis, C., Harris, A., Kingsman, S. and Naylor, S. (2000) The macrophage ^ a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7, 255^262. [17] Ishiura, M., Hirose, S., Uchida, T., Hamada, Y., Suzuki, Y. and Okada, Y. (1982) Phage particle-mediated gene transfer to cultured mamalian cells. Mol. Cell. Biol. 2, 607^616. [18] Bodmeirer, R., Chen, H.G. and Paeratakul, O. (1989) A novel approach to the oral delivery of nanoparticles. Pharm. Res. 6, 413^417. Cyaan Magenta Geel Zwart 26 J.R. Clark, J.B. March / FEMS Immunology and Medical Microbiology 40 (2004) 21^26 [19] Centers for Disease Control (1987) Morbid. Mortal. Wkly. Rep. 36, 353. [20] Klavinskis, L.S., Gao, L., Barn¢eld, C., Lehner, T. and Parker, S. (1997) Mucosal immunization with DNA-liposome complexes. Vaccine 15, 818^820. [21] Barrow, P.A. and Soothill, J.S. (1997) Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5, 268^271. FEMSIM 1652 15-12-03 [22] Reynaud, A., Cloastre, L., Bernard, J., Laveran, H., Ackermann, H.W., Licois, D. and Joly, B. (1992) Characteristics and di¡usion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Vet. Microbiol. 30, 203^212. [23] Weber-Dabrowska, B., Mulczyk, M. and Gorski, A. (2000) Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch. Immunol. Ther. Exp. (Warsaw) 48, 547^551. Cyaan Magenta Geel Zwart